Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia.
Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
Front Immunol. 2021 Mar 22;12:634127. doi: 10.3389/fimmu.2021.634127. eCollection 2021.
Sepsis is associated with a dysregulated inflammatory response to infection. Despite the activation of inflammation, an immune suppression is often observed, predisposing patients to secondary infections. Therapies directed at restoration of immunity may be considered but should be guided by the immune status of the patients. In this paper, we described the use of a high-dimensional flow cytometry (HDCyto) panel to assess the immunophenotype of patients with sepsis. We then isolated peripheral blood mononuclear cells (PBMCs) from patients with septic shock and mimicked a secondary infection by stimulating PBMCs for 4 h with lipopolysaccharide (LPS) with or without prior exposure to either IFN-γ, or LAG-3Ig. We evaluated the response by means of flow cytometry and high-resolution clustering cum differential analysis and compared the results to PBMCs from healthy donors. We observed a heterogeneous immune response in septic patients and identified two major subgroups: one characterized by hypo-responsiveness (Hypo) and another one by hyper-responsiveness (Hyper). Hypo and Hyper groups showed significant differences in the production of cytokines/chemokine and surface human leukocyte antigen-DR (HLA-DR) expression in response to LPS stimulation, which were observed across all cell types. When pre-treated with either interferon gamma (IFN-γ) or lymphocyte-activation gene 3 (LAG)-3 recombinant fusion protein (LAG-3Ig) prior to LPS stimulation, cells from the Hypo group were shown to be more responsive to both immunostimulants than cells from the Hyper group. Our results demonstrate the importance of patient stratification based on their immune status prior to any immune therapies. Once sufficiently scaled, this approach may be useful for prescribing the right immune therapy for the right patient at the right time, the key to the success of any therapy.
脓毒症与感染后炎症反应失调有关。尽管炎症被激活,但通常会观察到免疫抑制,使患者易发生继发感染。可以考虑针对恢复免疫的治疗,但应根据患者的免疫状态进行指导。在本文中,我们描述了使用高维流式细胞术 (HDCyto) 面板来评估脓毒症患者的免疫表型。然后,我们从感染性休克患者中分离外周血单核细胞 (PBMCs),并通过用脂多糖 (LPS) 刺激 PBMCs 4 小时来模拟继发感染,而 LPS 刺激前或同时预先暴露于 IFN-γ或 LAG-3Ig。我们通过流式细胞术和高分辨率聚类差异分析来评估反应,并将结果与健康供体的 PBMCs 进行比较。我们观察到脓毒症患者存在异质性免疫反应,并确定了两个主要亚组:一个以低反应性为特征 (Hypo),另一个以高反应性为特征 (Hyper)。Hypo 和 Hyper 组在 LPS 刺激后产生细胞因子/趋化因子和表面人白细胞抗原-DR (HLA-DR) 的表达方面表现出显著差异,这在所有细胞类型中都观察到。当在用干扰素γ (IFN-γ) 或淋巴细胞活化基因 3 (LAG-3) 重组融合蛋白 (LAG-3Ig) 预处理后再用 LPS 刺激时,与 Hyper 组相比,Hypo 组的细胞对两种免疫刺激剂的反应性更高。我们的结果表明,在进行任何免疫治疗之前,根据患者的免疫状态进行分层的重要性。一旦充分扩展,这种方法可能有助于在适当的时间为适当的患者开具适当的免疫治疗,这是任何治疗成功的关键。